Background: Human parechovirus (HPeV) and enterovirus (EV) infections are widespread and can lead to a broad range of symptoms, from the common cold to severe disease (SD). Because of the lack of Italian data, this 4-year retrospective cross-sectional study aimed to investigate the frequency, seasonality and molecular characteristics of EV and HPeV circulating in children younger than 5 years. Methods: A total of 812 samples were collected from children ≤5 years (56.5% males; median age: 20.6 months; interquartile range: 30.1 months) from September 2010 to August 2014. Two real-time RT-PCR assays were used for EV/HPeV and EV-D68 detection. Phylogenetic analysis was performed on the EV-VP1 gene and the HPeV-VP3/VP1 junction. Results: 16.1% and 5.2% of samples were EV-and HPeV-positive, respectively. One sample was EV-D68-positive. The majority (nearly 80%) of EV/HPeV-positive samples was detected in children ≤3 years, during the summer/autumn seasons. The risk of EV infection was higher in children presenting with SD, whereas the risk of infection from HPeV was higher in infants ≤1 year. Most (61.7%) of molecularly characterized EVs belonged to species B, followed by A (29.4%). The majority (66.7%) of characterized HPeVs were type 1, followed by types 3 (20%) and 6 (13.3%). Conclusions: This study shows the significant impact of EV/HPeV circulation in children, particularly among those ≤3 years and during and early autumn, with different pattern of viral strains. The implementation of a national surveillance system could clarify the epidemiologic and clinical characteristics of these viruses in the general population.
H uman parechoviruses (HPeVs) and enteroviruses (EVs) are small, nonenveloped, single-stranded RNA viruses and belong to the large and growing Picornaviridae family. 1 In the past few years, there has been a dramatic increase in the number of novel picornaviruses identified and genomes sequenced, thanks to the continuous updates in molecular assays. 2 So far, 16 genotypes of HPeV have been identified, and there are over 100 EVs that infect humans, which are currently classified into four species, A-D, according to molecular and antigenic properties. 2 Although HPeVs and EVs belong to genetically distinct genera, they share many epidemiologic and clinical features. EVs and HPeVs are mainly transmitted by fecal-oral and respiratory routes. 3, 4 These viruses circulate worldwide and often show seasonal patterns of incidence in both temperate and tropical climates, although seasonality is typically more marked in the former, with infections more common in summer and early autumn. 3 EV and HPeV infections can result in a wide range of clinical diseases that involve the gastrointestinal or respiratory tracts and the central nervous system (CNS). They can cause numerous diseases, from gastroenteritis and the common cold to life threatening encephalitis, meningitis, paralysis and hepatitis.
1,4-6 EV and HPeV infections are strongly associated with age and they occur most frequently in early childhood. 7 Although these infections are mostly asymptomatic, new borns are considered at higher risk for severe EV and HPeV infections because of their immature immune system. 7, 8 Since August 2014, an increase in infections caused by EV-D68 has been reported 9 and the association with severe respiratory illness, polio-like acute flaccid paralysis and fatal cases has been documented. 10 Limited data on the circulation of EVs and HPeVs in Italy have been reported so far. [11] [12] [13] In addition, since no HPeV and nonpolio EV surveillance is currently ongoing in Italy-as opposed to in other countries 14, 15 -the impact and epidemiologic characteristics of these viruses are difficult to delineate. Therefore, this cross-sectional retrospective 4-year study aimed to describe the epidemiologic and molecular characteristics of EVs and HPeVs circulating in children ≤5 years in Lombardy (Northern Italy) from 2010 to 2014. The circulation of EV-D68 was intentionally investigated.
METHODS

Study Population
From September 1, 2010 to August 31, 2014, 812 clinical samples (rectal or respiratory swabs) were collected from children younger than 5 years in Lombardy (a region of Northern Italy accounting for nearly 10 million inhabitants). The samples were collected from either hospitalized children or outpatients and were analyzed in the framework of the routine diagnostic virologic laboratory activities of the Department of Biomedical Sciences for Health, University of Milan (Milan, Italy).
The median age of children studied was 20.6 months [interquartile range (IQR): 30.1 months] and 42% were under 1 year; 56.5% were males. Most samples were collected during winter and spring (48.5% and 32.0%, respectively). Forty percent of samples were collected from children presenting with symptoms of gastrointestinal infections (GI), 38.4% from children presenting with symptoms of upper respiratory tract infections (URTI) and the remaining 21.6% from individuals with symptoms of severe disease (SD), such as CNS infections (acute flaccid paralysis, meningitis and encephalitis), sepsis, febrile illness with seizures and
Detection of the EV/HPeV Genome in Clinical Specimens
RNA was extracted from each specimen using the Invisorb Spin Virus RNA Mini kit (Stratec Molecular, Birkenfeld, Germany). To detect simultaneously the EV and HPeV genomes, a one-step real-time multiplex RT-PCR assay was performed using primer/probe sets specific for the 5ʹnontranslated region (5ʹ NTR) as previously described. 16 At the same time, to check the extraction performance, the amplification of human RNase P gene (RNP) was carried out by TaqMan RNase P assay (ABY dye/QSY probe; Thermofisher Scientific, Waltam, MA) by using the same thermal profile as the EV/HPeV assay. EV-positive samples were further analyzed by a one-step real-time RT-PCR assay to detect the presence of the EV-D68 genome using a specific primer/probe set as described by Poelman et al. 9 The real-time RT-PCR reactions were carried out in a 7300 real-time PCR System (Thermofisher scientific, Waltam, MA). Each sample should exhibit RNP curve at or before the 40 th cycle threshold (C T ). A sample was considered positive for EV/HPeV and/or EV-D68 when a curve crosses the threshold line before or at the 40 th C T .
Molecular Characterization and Phylogenetic Analysis of EV/HPeV Nucleotide Sequences
The molecular characterization of EV/HPeV was performed by sequence analysis of the VP1 gene (nt. 2602-2977) specific for EVs 17 and the VP3/VP1 junction (nt. 2159-2458) specific for HPeVs. 8 RT-PCR products were purified with a commercial kit (NucleoSpin Gel and PCR Clean-up kit, Macherey-Nagel, Duren, Germany). The nucleotide sequences were obtained by automated DNA sequencing based on fluorescent dye terminator on the genetic analyzer ABI PRISM 3730XL (Thermofisher scientific, Waltam, MA).
Multiple sequence alignments were created using ClustalW, implemented in the BioEdit program. 18 Phylogenetic trees with the EV and HPeV sequences were constructed by Neighbor-Joining method 19 and Kimura 2-Parameter model, 20 using the MEGA package, version 6.0. 21 A bootstrap analysis (n = 1000) was performed and major branches with bootstrap values >70% were identified as distinct groups. 22 The nucleotide reference sequences used in the construction of phylogenetic trees were obtained from the GenBank, National Center for Biotechnology Information (NCBI) 23 and are summarized in Supplemental Tables (see Table, 
Statistical Analysis
Statistical analysis was performed using the Open Source Epidemiologic Statistics for Public Health OpenEpi, version 3.03. 24 The risk of infection was expressed as number of individuals with a laboratory-confirmed infection out of the total number of individuals with specific characteristics. The 95% confidence intervals (95% CIs) were calculated. Conditional maximum likelihood estimate (CMLE) and exact confidence limits for a common odds ratio (OR) were computed. Proportions between groups were compared using the, mid-P Exact test based on binomial distribution. For continuous variables, the paired t-test was used. A P value <0.05 was considered significant (two-tailed test).
RESULTS
Detection of EV and HPeV in Clinical Specimens
During the 4-year study, 812 clinical samples were collected. A total of 173 of 812 tested samples (21.3%; 95% CI: 18.6%-24.3%) were positive for EV/HPeV real-time RT-PCR detection: 131 (16.1%; 95% CI: 13.8%-18.8%) were EV-positive and 42 (5.2%; 95% CI: 3.8%-6.9%) were HPeV-positive. EV and HPeV were codetected in one specimen. Among EV-positive samples, 1 (1/131; 0.8%; 95% CI: 0%-4.6%) was positive for EV-D68 by specific real-time RT-PCR.
The proportion of EV-positive samples by year of study ranged from 12.7% (95% CI: 9.1%-17.4%) in the second year to 23.1% (95% CI: 17.8%-29.3%) in the first year (P = 0.004). The highest proportion of HPeV-positive samples was reported in the third year of study (8.6%; 95% CI: 5.2%-13.7%) whereas the lowest was reported in the fourth year (2.8%; 95% CI: 1.0%-6.6%; P = 0.021).
The characteristics of EV-and HPeV-positive children are summarized in Table 2 . A total of 56.5% of EV-positive and 64.3% of HPeV-positive cases were males (P = 0.38). The median age of EV-positive individuals was equal to 15 months (IQR: 28.1 months; range: from 1 day to 5 years), and 79.4% (104/131) were younger than 3 years old. EV-positive children identified during the third year of study (2012/2013) were significantly younger than those identified during the other years of study (P < 0.04). The median age of HPeVpositive individuals was 12 months (IQR: 24 months; range: 8 days-4 years), and the majority (36/42: 85.7%) were less than 3 years old. No age differences of HPeV-positive children were observed in the 4 years of study (P > 0.05), as well as between EV-and HPeV-infected children (P = 0.34). However, EV-and HPeV-positive children were significantly younger than those who were EV/HPeV-negative (EV positive vs. EV/HPeV negative: 15 vs. 23.8 months, P = 0.01; HPeVpositive vs. EV/HPeV negative: 12 vs. 23.8 months; P = 0.005).
The frequency of detection of EVs was higher in the SD group than in the GI (26.9% vs. 17.2%; P = 0.012) and URTI groups (26.9% vs. 8.9%; P < 0.001). The proportions of HPeVpositive samples were similar in the 3 groups (P > 0.05), with 6.5% in the GI group, 3.5% in the URTI group and 5.7% in the SD group. These data are summarized in Table 3 .
As presented in Table 3 , the risk of infection from EV was similar in the 3 age groups with no significant differences and it was higher among children with SD than in those with GI (OR: 2.1, 95% CI: 1.3-3.5) or URTI (OR: 1.7, 95% CI: 1.1-2.7). The risk of infection from HPeV was significantly higher in the 0-to 12-month age group than in the 37-to 60-month age group (OR: 2.5, 95% CI: 1.1-6.8); no differences in the risk of infection from HPeV were observed among children with different diseases.
The seasonal distribution of EV and HPeV detections showed that the proportions of EV-and HPeV-positive samples were higher during summer (EV: 44.6%; HPeV: 8.9%), followed by autumn (EV: 23.5%; HPeV: 6.9%), spring (EV: 13.1%; HPeV: 5.8%) and winter (EV: 12.2%; HPeV: 3.8%; Table 3 ). As shown in Table 3 , the risk of infection from EV was higher in summer than in the other seasons (OR: 2.6, 95% CI: 1.3-5.3 vs. autumn; OR: 5.8, 95% CI: 3.1-10.6 vs. winter, OR: 5.3, 95% CI: 2.8-10.1 vs. spring). No significant differences were found for the risk of infection from HPeV by season. Figure 1 shows the monthly distribution of virus detection. EVs circulated throughout the year with an increased proportion detected during the summer (with a peak in July) and in early autumn (September). HPeV detection was distributed throughout the year except for May and August, and no specific temporal distribution was observed.
Molecular Characterization and Phylogenetic Analysis of EV/HPeV Nucleotide Sequences
Overall, 25.9% (34/131) and 71.4% (30/42) of EV-and HPeV-positive samples, respectively, were sequenced.
Enterovirus
The majority (21/34; 61.8%) of characterized EV belonged to species B, followed by A (10/34; 29.4%). Two samples (2/34; 5.9%) belonged to specie C. One sample was genotyped by realtime RT-PCR as EV-D68 (1/34; 2.9%). Figure 2 shows the distribution of the EV genotypes identified. Overall, 15 different EV genotypes were detected; almost all (12/15; 80%) were identified in children 0-12 months old, whereas only 3 different genotypes (3/15; 20%) were detected in the 37-60 months age group (P = 0.001).
Echovirus 11 (species B) was the genotype most frequently detected (8/34; 23.5%): in 75% (6/8) of cases, it was identified in children with SD (acute hepatitis, meningitis and acute flaccid paralysis), and particularly in neonates younger than 1 month. 11.8% of genotyped EV-positive samples were CAV4 (species A) and CBV5 (species B), respectively: CAV4 was detected mainly Risk of infection is expressed as the number of subjects with a laboratory-confirmed infection out of the total number of subjects. 95% CIs are reported in brackets.
in children presenting with GI during winter, whereas CBV5 was identified exclusively in samples collected from children presenting with GI during summer. CBV4 was detected in 8.8% (3/34) of genotyped samples: 2 out of these 3 cases were neonates <15 days old with SD (hepatitis and sepsis, respectively). The only EV-D68 identified was in a 9-month-old female with GI; EV-71 was identified in a 26-day-old male with CNS disease.
Three different trees were obtained from the phylogenetic analysis of EV VP1 sequences, one for each species (A, B and C) identified by sequence analysis (see 
Human Parechovirus
The HPeV type most frequently detected was type 1 (20/30; 66.7%), followed by types 3 (6/30; 20%) and 6 (4/30; 13.3%). HPeV-1 and HPeV-3 were mainly (70% and 66.7%, respectively) identified in children younger than 1 year, whereas HPeV-6 was mainly detected (75%) in 13-36 months age group. The majority (12/20; 60%) of HPeV-1-positive children had GI symptoms. Phylogenetic analysis of the HPeV sequence dataset (Fig. 3) showed that the studied sequences were assembled into 3 different genetic groups with the reference sequences of HPeV types 1, 3 and 6 with significant bootstrapping values (96%, 100% and 100%, respectively).
CONCLUSIONS
This retrospective cross-sectional study described the epidemiologic and molecular characteristics of EVs and HPeVs circulating in children up to 5 years old in Lombardy over a 4-year period (2010-2014) as identified by real-time RT-PCR and direct genotyping. As several outbreaks of severe respiratory illness caused by EV-D68 have been reported since 2014, the circulation of EV-D68 was intentionally investigated.
The overall proportion of EV-positive samples in our study population was 16.1%, fluctuating from 12.7% in the second year of study (2011/2012) to 23.1% in the first year (2010/2011). During the 4-year study period, the overall proportion of HPeV-positive samples was 5.2% and the highest proportion was reported in the third year of study (8.6%), compared with the lowest in the fourth year (2.8%). The global rates of EV/HPeV infections found in our study were probably significantly enhanced by the use of real-time RT-PCR detection assay, capable of high specificity and sensitivity. 16 The age distribution of EV/HPeV infections observed in our study is concordant with previous investigations. 7, 25 In fact, in our study, the majority (80%-85%) of EV/HPeV-positive children were younger than 3 years and their median age were similar (15 vs. 12 months). It is interesting to note that EV-and HPeV-positive children were significantly younger than the EV/HPeV-negative children. The risk of infection from HPeV was significantly higher in children younger than 1 year compared with the 3-to 5 year-old children. The lower frequency of HPeV infections in older children is consistent with previous seroepidemiologic studies documenting 72% seroprevalence of antibodies directed against HPeV-1 by the age of 2, reaching 99% in adulthood. 26 This age-trend was less marked for EV infections: no significant differences in the risk of infection from EV were observed between the 3 age groups considered in this study.
In our study, the frequencies of EV-and HPeV-positive samples (17.2% and 6.5%, respectively) collected from children with GI were higher than those reported by Rovida et al, 13 where the frequencies of EV and HPeV infections in the pediatric/adult population with gastroenteritis were 3% and 1%, respectively. Similarly, the proportion of EV-positive samples found among studied children with URTI was nearly 9%, higher than that reported by Puenpa et al, 27 where EV prevalence in children up to 12-year old with respiratory symptoms was 5.3%. In our URTI group, the proportion of HPeV detections was 3.5%, similar to results found (3%) by Sharp et al 28 in a systematic study on respiratory samples collected from children. However, it was higher than that reported in the study by Harvala et al 8 where, despite HPeV infections being investigated in respiratory specimens collected from all age groups, it was detected only in children younger than 5 years with a frequency of about 1%.
The proportion of EV-and HPeV-positive samples among children presenting with SD was approximately 27% and 6% for EV and HPeV, respectively. These findings differ from results reported in the study by Wolthers et al, 29 where EV and HPeV infections were identified in 14% and 4.6% of cases, respectively. However, it should be considered that the population analyzed by Wolthers et al 29 consisted of children younger than 5 years presenting with sepsis-like illness and meningitis, while, in our study, a larger spectrum of diseases (CNS infections, acute flaccid paralysis, encephalitis, febrile illness with seizures and acute hepatitis) was considered. It is interesting to note that in our study the risk of infection from EV was 2-fold higher among children with SD than in those with GI or URTI. No differences in the risk of infection from HPeV were observed among children with different diseases.
The seasonal distribution of EV circulation is concordant with other studies. 7 In fact, although EVs were detected throughout the year, an increased proportion of detections were observed in summer and in early autumn; in addition, the risk of infection during summer was higher than in other seasons. These data overlapped with the seasonal patterns of incidence in temperate climates. 3 Previous investigations on the seasonality of HPeV infections have observed greater frequencies of infections in late summer and early winter and have provided evidence for a biannual cycle of HPeV infection. 30 However, a recent study on HPeV distribution in Denmark has not shown this seasonal pattern. 25 The molecular characterization of circulating EVs and HPeVs was carried out by direct genotyping. Most of the characterized EVs belonged to species B (CAV9, CBV3, CBV4, CBV5, E7, E9, E11, E30), followed by A (CAV2, CAV4, CAV5, CAV6, EV-71), C (CAV22) and D (EV-D68). Almost all (80%) of the genotypes identified in this study were recognized in children 0-to 12-month old, whereas only 3 different genotypes were detected in the 37-to 60-month-age group. This evidence suggests a greater heterogeneity of circulating EV genotypes in early infancy, whereas fewer genotypes circulate later in infancy, probably because of a progressive gain in immunity. However, the mechanism of acquired immunity remains unclear. 31 Echovirus 11 (species B) was the genotype most frequently detected, particularly in neonates <1-month old with SD, such as acute hepatitis, meningitis and acute flaccid paralysis. In the study by Tapparel et al, 32 EV genotypes were associated with specific symptomatology after the most common association in our study, all EVs belonged to species B (except CBV5), EV71, CAV6 (species A) and CAV22 (species C) were related to GI, URTI and SD, as reported by Tapparel et al. 32 On the contrary, CAV2, CAV4, CAV5 and CBV5 were detected in samples collected from children presenting with GI (CAV4 and CBV5) or URTI (CAV2, CAV4, CAV5), although they have been generally related to SD. 32 Nonetheless, the definition of any association between EV genotypes and clinical outcome was out of the aim of our study either because of the scarcity of clinical information or the limited number of EV-positive samples genotyped. Further studies of sequence analysis of circulating EVs will allow the clarification of this issue. In addition, the application of deep-sequencing techniques will permit a more detailed investigation into the possibility of coinfection with multiple EV genotypes. PCR amplification of nucleic acids combined with deep-sequencing techniques and bioinformatics analyses is a promising strategy for identifying pathogens in clinical and public health settings. It allows the characterization of different known pathogens simultaneously and of novel pathogens that elude conventional testing. However, major hurdles for its routine use exist, including cost, turnaround time and especially sensitivity of the assay, as the detection limit is dependent on viral load. 33 EV-D68 has been recently associated with cases of severe respiratory tract infections in Europe and North America. 9, 34 According to the European society for clinical virology (ESCV) report, 9 in Europe the rate of EV-D68 positive respiratory samples among those collected from patients younger than 16 years admitted to hospital and presenting with any respiratory symptoms, from July 1, 2014 to December 1, 2014, was 2.1%. In Italy, EV-D68 was detected in 4.5% of samples considered. In our study, only one specimen (collected in 2010 from a 9-month-old female with gastrointestinal infection) resulted positive for EV-D68. The low frequency of EV-D68 detection in our series was probably due to the interval considered in this study spanning from September 2010 to August 2014, preceding the period when EV-D68 has been reported in Europe (end of 2014). 9 Only 3 types of HPeV were recognized in HPeV-positive samples detected over the 4-year period: types 1, 3 and 6. As expected, 35 HPeV-1 was the type most frequently detected (66.7%), followed by type 3 (20%) and 6 (13.3%). HPeV-3 was mainly identified in children younger than 1 year, as also reported elsewhere, 29 whereas HPeV-6 was mainly detected in the 13-36 months age group. The small number of HPeV-positive samples identified in our sample series did not allow delineation of the epidemiologic and clinical features of HPeV types.
Although EVs and HPeVs are variable viruses, the sequences obtained in our study shared high similarity (93%-100%) with those included in the Genbank database. This result was also supported by phylogenetic analysis that reported high bootstrap values and confirmed the robustness of different nodes that included sequences obtained from our samples. From phylogenetic analysis, no specific infection clusters were found may be because of the limited number of sequences. Study with a greater number of sequences could better explain the distribution of different genotypes during the different epidemic seasons and identify possible epidemic clusters.
In conclusion, the results of this 4-year retrospective study showed that EVs and HPeVs have a significant impact in children younger than 5 years old and particularly among children in their first year of life, leading to different clinical outcomes. These viruses were shown to circulate at a different extent throughout the year with increasing incidence during summer and early autumn. Although only the 3 most common HPeV types were identified in this study, a wide range of EV genotypes were observed, mainly in children less than 1 year old, suggesting a complex epidemiologic pattern of EVs.
